Acta Pharmaceutica Sinica B 2022;12(6):2963–2964

Chinese Pharmaceutical Association
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

www.elsevier.com/locate/apsb
www.sciencedirect.com



CORRECTION

Author correction to "Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers" [Acta Pharmaceutica Sinica B 11 (2021) 355–372]

Tingting Jiang[a,†], Guan Wang[a,†], Yao Liu[a,†], Lu Feng[a], Meng Wang[a], Jie Liu[a], Yi Chen[b,*], Liang Ouyang[a,*]

[a]*State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China*
[b]*State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China*

The authors regret that there are some compound structure errors and misplacement of Ref. Nos. in the article due to the mistake of copying and pasting in the process of assembling figures and negligence in the proofreading. Although it does not affect the conclusion, it is obvious errors. The authors have now modified as below.

The authors apologize for any inconvenience caused to the journal and readers.

1. Ref. 23 should be replaced with 'Cabozantinib in patients with RET fusion-positive advanced non-small cell lung cancer and those with other genotypes: ROS1 or NTRK fusions or increased MET or AXL activity. ClinicalTrails.gov, 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT01639508. Ref. 108 should be replaced with 'Marx MA, La Greca SD, Chen J, Wessel MD, Arcari JT, inventors. Pfizer Prod Inc., assignee. Preparation of pyrrolopyrimidine derivatives useful in cancer treatment. 2005 Dec 08, WO2005116035A1'. Ref. 110 of compound **39** should be replaced with Ref. 97 on page 365. Ref. 112 of compound **41** should be replaced with Ref. 110 on page 365. Ref. 118 of compound **45** should be replaced with Ref. 117 on page 367; Ref. of 107 for compound **46** should be replaced with 'Bagal SK, Omoto K, Blakemore DC, Bungay PJ, Bilsland JG, Clarke PJ, et al. Discovery of allosteric, potent, subtype selective and peripherally restricted TRKA kinase inhibitors. *J Med Chem* 2019;**62**:247–65' on page 368.

2. Ref. 109 for compound **37** should be replaced with 'El-Damasy AK, Cho NC, Nam G, Pae AN, Keum G. Discovery of a nanomolar multikinase inhibitor (KST016366): a new benzothiazole derivative with remarkable broad-spectrum antiproliferative

DOI of original article: https://doi.org/10.1016/j.apsb.2020.05.004.
*Corresponding authors. Tel./fax: +86 28 85503817.
E-mail addresses: toddychan@163.com (Yi Chen), ouyangliang@scu.edu.cn (Liang Ouyang).
†These authors made equal contributions to this work.
Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.

https://doi.org/10.1016/j.apsb.2022.02.028

activity. *Chem Med Chem* 2016;**11**:1587−95' on page 365. In Fi. 12, the activity of compound **37** (TRKA/B/C IC_{50} = 1 nmol/L) should be corrected to TRKA IC_{50} = 3.8 nmol/L, TRKB IC_{50} = 4.4 nmol/L.

3. In Fis. 12 and 14, the activity of compound **40** (TRKA IC_{50} = 3.8 nmol/L, TRKB IC_{50} = 4.4 nmol/L) should be corrected to TRKA IC_{50} = 1.67 nmol/L; the structure of compounds **41** and **45** should be corrected as the following illustration, and the IC_{50} values of TRKA were 18 and 1.4 nmol/L, respectively.



41

TRKA IC_{50} = 18 nmol/L

TIE-2 IC_{50} = 5 nmol/L



45

TRKA IC_{50} = 1.4 nmol/L